Los Angeles-based Cedars-Sinai Technology Ventures has officially launched Coronet Ventures Netherlands, its third international healthcare-focused investment fund, aimed at supporting early-stage health and life sciences startups across the Netherlands.
“At Cedars-Sinai, we are dedicated to advancing innovations that improve patient care while making healthcare more efficient and cost-effective. With Coronet Netherlands, we are building new global partnerships to access leading science, accelerate clinical translation, and help bring breakthrough technologies to patients faster,” says James D. Laur, JD, chief executive of Intellectual Property and Health Ventures at Cedars-Sinai, and co-founder of the Cedars-Sinai Accelerator.
Based out of Los Angeles, Cedars-Sinai specialises in the clinical care and research of heart disease, cancer, and brain disorders, among other areas.
Investing €43.4M over the next decade
Announced at HLTH Europe 2025, the new fund reflects Cedars-Sinai’s deepening commitment to advancing global healthcare innovation.
With an investment capacity of $50M (approximately €43.4M) over the next decade, Coronet Ventures Netherlands will back Dutch startups working on cutting-edge biomedical and health tech solutions, with a focus on technologies that can scale into the U.S. market.
Startups supported by the fund will have access to Cedars-Sinai’s clinical data environment, opportunities for pilot testing, and deep commercialization support.
The initiative is part of Cedars-Sinai Technology Ventures, the organisation’s innovation arm designed to connect researchers, entrepreneurs, and investors with the tools and support needed to bring impactful solutions to patients.
The Netherlands-based fund joins a growing international portfolio that includes Coronet Ventures (U.S.) and Coronet Ventures Singapore.
“This partnership allows us to create a platform with underlying capital that also offers deep clinical validation and commercialization support to help healthcare and biotechnology companies scale more quickly into the U.S.,” says Nirdesh K. Gupta, PhD, managing partner of Cedars-Sinai Intellectual Property Company.
Cedars-Sinai Technology Ventures x Dutch innovators
The new venture fund builds on four years of collaboration between Cedars-Sinai Technology Ventures and Dutch innovators.
Since 2021, Cedars-Sinai Technology Ventures has met with startups from the Netherlands to explore opportunities with the Cedars-Sinai Accelerator, a Technology Ventures subsidiary that supports early-stage companies with mentorship and a $100,000 investment.
Notably, two Dutch startups have already participated in the accelerator program. They are
HealthPlus.ai: Based out of Amsterdam, the company uses electronic health records and artificial intelligence to predict patients’ infection risk and assist with early medical intervention.
Syntho: Amsterdam-based company uses artificial intelligence to generate synthetic healthcare data used by medical researchers. Syntho has since completed a pilot program with Cedars-Sinai and is in discussions to collaborate with the organization’s Artificial Intelligence Lab.
01
From telecom veteran to Dutch Startup Visa success: The Jignesh Dave story